BACKGROUND: Neuronal loss in multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), correlates with permanent neurological dysfunction. Current MS therapies have limited the ability to prevent neuronal damage. METHODS: We examined whether oral therapy with SRT501, a pharmaceutical grade formulation of resveratrol, reduces neuronal loss during relapsing-remitting EAE. Resveratrol activates SIRT1, an NAD+-dependent deacetylase that promotes mitochondrial function. RESULTS: Oral SRT501 prevented neuronal loss during optic neuritis, an inflammatory optic nerve lesion in MS and EAE. SRT501 also suppressed neurological dysfunction during EAE remission, and spinal cords from SRT501-treated mice had significantly higher axonal density than vehicle-treated mice. Similar neuroprotection was mediated by SRT1720, another SIRT1-activating compound; and sirtinol, an SIRT1 inhibitor, attenuated SRT501 neuroprotective effects. SIRT1 activators did not prevent inflammation. CONCLUSIONS: These studies demonstrate that SRT501 attenuates neuronal damage and neurological dysfunction in EAE by a mechanism involving SIRT1 activation. SIRT1 activators are a potential oral therapy in MS.
BACKGROUND:Neuronal loss in multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), correlates with permanent neurological dysfunction. Current MS therapies have limited the ability to prevent neuronal damage. METHODS: We examined whether oral therapy with SRT501, a pharmaceutical grade formulation of resveratrol, reduces neuronal loss during relapsing-remitting EAE. Resveratrol activates SIRT1, an NAD+-dependent deacetylase that promotes mitochondrial function. RESULTS: Oral SRT501 prevented neuronal loss during optic neuritis, an inflammatory optic nerve lesion in MS and EAE. SRT501 also suppressed neurological dysfunction during EAE remission, and spinal cords from SRT501-treated mice had significantly higher axonal density than vehicle-treated mice. Similar neuroprotection was mediated by SRT1720, another SIRT1-activating compound; and sirtinol, an SIRT1 inhibitor, attenuated SRT501 neuroprotective effects. SIRT1 activators did not prevent inflammation. CONCLUSIONS: These studies demonstrate that SRT501 attenuates neuronal damage and neurological dysfunction in EAE by a mechanism involving SIRT1 activation. SIRT1 activators are a potential oral therapy in MS.
Authors: N A Losseff; L Wang; H M Lai; D S Yoo; M L Gawne-Cain; W I McDonald; D H Miller; A J Thompson Journal: Brain Date: 1996-12 Impact factor: 13.501
Authors: V Parisi; G Manni; M Spadaro; G Colacino; R Restuccia; S Marchi; M G Bucci; F Pierelli Journal: Invest Ophthalmol Vis Sci Date: 1999-10 Impact factor: 4.799
Authors: Jennifer B Fisher; Dina A Jacobs; Clyde E Markowitz; Steven L Galetta; Nicholas J Volpe; M Ligia Nano-Schiavi; Monika L Baier; Elliot M Frohman; Heather Winslow; Teresa C Frohman; Peter A Calabresi; Maureen G Maguire; Gary R Cutter; Laura J Balcer Journal: Ophthalmology Date: 2006-01-10 Impact factor: 12.079
Authors: L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham Journal: Ann Neurol Date: 1996-03 Impact factor: 10.422
Authors: S Anand Trip; Patricio G Schlottmann; Stephen J Jones; Daniel R Altmann; David F Garway-Heath; Alan J Thompson; Gordon T Plant; David H Miller Journal: Ann Neurol Date: 2005-09 Impact factor: 10.422
Authors: Feng Zhang; Suping Wang; Li Gan; Peter S Vosler; Yanqin Gao; Michael J Zigmond; Jun Chen Journal: Prog Neurobiol Date: 2011-09-10 Impact factor: 11.685
Authors: Joseph A Baur; Zoltan Ungvari; Robin K Minor; David G Le Couteur; Rafael de Cabo Journal: Nat Rev Drug Discov Date: 2012-06-01 Impact factor: 84.694
Authors: Scott D Walter; Hiroshi Ishikawa; Kristin M Galetta; Reiko E Sakai; Daniel J Feller; Sam B Henderson; James A Wilson; Maureen G Maguire; Steven L Galetta; Elliot Frohman; Peter A Calabresi; Joel S Schuman; Laura J Balcer Journal: Ophthalmology Date: 2012-02-23 Impact factor: 12.079
Authors: Vamshi K Nimmagadda; Christopher T Bever; Narasimha R Vattikunta; Saifi Talat; Vakas Ahmad; Naveen K Nagalla; David Trisler; Susan I V Judge; Walter Royal; Krish Chandrasekaran; James W Russell; Tapas K Makar Journal: J Immunol Date: 2013-04-01 Impact factor: 5.422
Authors: Vamshi K C Nimmagadda; Tapas K Makar; Krish Chandrasekaran; Avinash Rao Sagi; Jayanta Ray; James W Russell; Christopher T Bever Journal: J Neuroimmunol Date: 2016-07-17 Impact factor: 3.478